Moleculin Biotech, Inc. (MBRX) is a publicly traded Healthcare sector company. As of September 18, 2026, MBRX trades at $0.76 with a market cap of $15.19M and a P/E ratio of -0.03. MBRX moved +0.44% today. Year to date, MBRX is -78.64%; over the trailing twelve months it is -92.49%. Its 52-week range spans $0.16 to $91.25. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces MBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for MBRX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $0.76 |
| Market Cap | $15.19M |
| P/E Ratio | -0.03 |
| EPS | $-28.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $91.25 |
| 52-Week Low | $0.16 |
| Volume | 279.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-33.56M |
| Gross Margin | 0.00% |
3 analysts cover MBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.